Polθ-IN-4
Polθ-IN-4 is an orally active prodrug of a DNA polymerase θ (Polθ) inhibitor with Kms of 3.7, 3.7 and 5.2 μM in human, mouse and rat recombinant alkaline phosphatases. Polθ-IN-4 that inhibits Polθ activity by targeting its ATP-dependent helicase domain. Polθ-IN-4 demonstrates significant anti-tumor activity in multiple animal experiments. Polθ-IN-4 can be used for the studies of breast cancer and ovarian cancer[1].
Product Specifications
CAS Number
[3043810-73-4]
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/polθ-in-4.html
Concentration
10mM
Purity
98.71
Solubility
DMSO : 17.5 mg/mL (ultrasonic)
Smiles
ClC1=NC=C(OC)C(C2=C(C(/N=C3N(COP(O)(O)=O)N=C(OC)S/3)=O)C=NC(C)=C2)=C1
Molecular Formula
C17H17ClN5O7PS
Molecular Weight
501.84
References & Citations
[1]Janos B, et al. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof, WO2024121290A1, 2024-06-13
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Shigella dysenteriae serotype 1 NADH-quinone oxidoreductase subunit N (nuoN), partial
